Diligence report Healthcare services, radiology practice management, teleradiology and imaging AI workflows Private unicorn / growth-equity backed radiology platform

Radiology Partners

Radiology Partners Startup Diligence Report

Public materials support a real, national radiology platform that is trying to translate clinical scale into defensible AI and workflow software. The diligence question is not existence; it is whether leveraged services economics, customer durability, corporate-practice compliance and AI-enabled operating leverage are strong enough to justify a roughly unicorn-level valuation.

Company profile

Radiology Partners Startup Diligence Report

Radiology Partners is eligible for diligence as an active private company with meaningful scale and increasing productization, but public evidence also highlights leverage stress, sparse customer economics disclosure and payer/regulatory-adjacent litigation risk.

Website: www.radpartners.com
Sector: Healthcare services, radiology practice management, teleradiology and imaging AI workflows
Geography: United States
Stage: Private unicorn / growth-equity backed radiology platform
Known aliases: RadPartners, RP, Radiology Partners, Inc.
Report version: 1.0
Timezone: America/Chicago

Executive summary

Strengths

Investor, market-database and company-owned sources support that Radiology Partners remained active and private as of 2026-06-17.
The company publicly disclosed a February 2024 recap featuring approximately $720M of new equity, reduced debt and extended maturities.
Radiology Partners publicly markets a layered offering spanning hospital services, practice infrastructure, RPX AI and MosaicOS/Mosaic Reporting.
The public legal disclaimer and financing language support a physician-led, subsidiary-based practice structure rather than a single licensed care entity.

Risks

Public financing disclosure does not substitute for audited revenue quality, and S&P-linked reporting points to cash-flow and leverage stress.
Scale is public, but top-customer revenue concentration, churn and renewal economics are not.
The 2024 Trinity-related relationship loss shows that large-system relationships can turn and may be sensitive to outsourcing or corporate-practice concerns.
Aetna litigation tied RP to No Surprises Act and corporate-practice allegations even though the case was later dismissed.

Gaps

Audited financials, revenue/EBITDA bridge, debt documents, covenant headroom, cash-flow waterfall and current forecast model.
Fully diluted cap table, investor rights, liquidation preferences, ownership by physician entities and debt/term-loan schedules.
Top-15 customers, >5% customer concentration, renewal cohorts, churn/NRR, payer mix and site-level profitability.
Product pricing, software versus services mix, implementation metrics, model-evaluation results and AI governance artifacts.
Practice-management agreements, payer contracts, insurance limits, regulatory correspondence and litigation reserve analysis.

Recommended next steps

Run full financial and debt diligence before relying on headline valuation or liquidity claims.
Request a customer concentration pack covering top accounts, churn, terminations and any at-risk health-system relationships.
Have healthcare counsel review corporate-practice structure, No Surprises Act workflows, payer arbitration files and state compliance controls.
Benchmark RP win/loss, pricing and retention against national teleradiology, outpatient imaging and practice-management competitors.
Validate whether RPX AI, Mosaic and partner-led AI products are margin-accretive software layers or primarily service-enablement tools.

Risk register

high high likelihood

R-001: Financial opacity and leverage risk

Public sources show a large 2024 recap and liquidity claim, but not audited revenue quality, covenant headroom, gross margin, EBITDA or consistent free-cash-flow performance; S&P-linked commentary suggests leverage remains material.

Diligence request: Request audited financials, debt schedules, covenant model, monthly cash bridge and downside case by practice entity.

high medium likelihood

R-002: Cap-table and ownership opacity

Public signals show private ownership, physician stake and large financial sponsors, but not current diluted ownership, preferences, warrants, debt rights or liquidation waterfall.

Diligence request: Obtain the current cap table, board consents, financing docs and debt/equity waterfall.

high medium likelihood

R-003: Customer concentration and retention opacity

RP publicly discloses broad facility counts and selected affiliates, but not top customers, customer-level revenue, renewal schedules or churn metrics.

Diligence request: Request top-customer revenue schedule, churn/NRR, contract terms and customer references.

high medium likelihood

R-006: Relationship churn and corporate-practice backlash

The Trinity-related relationship loss and civil allegations around corporate-practice and arbitration conduct suggest that large outsourced radiology relationships can be politically or operationally fragile.

Diligence request: Review top at-risk accounts, termination history, customer complaints and state-law compliance memos.

high medium likelihood

R-007: Clinical AI safety and validation risk

RP publicly claims broad AI deployment and new AI-native products, but public validation, patient-safety and model-governance detail remains thinner than deployment claims.

Diligence request: Request model-evaluation results, escalation protocols, AI incident log and clinical-governance committee materials.

high medium likelihood

R-009: Payer litigation and reimbursement-process exposure

The Aetna dispute put RP’s billing/arbitration conduct into public view and, together with financing stress, elevates reimbursement-process risk.

Diligence request: Have counsel review all payer disputes, arbitration workflows, reserve analysis and state/federal reimbursement compliance controls.

medium high likelihood

R-005: Competitive pressure and pricing opacity

RP competes in a crowded outsourced radiology and teleradiology market, yet public pricing and win/loss evidence are limited.

Diligence request: Collect win/loss reports, pricing decks, buyer references and competitor benchmark analysis.

medium medium likelihood

R-004: Third-party AI and cloud dependency

Public product and R&D materials imply dependency on AWS HealthImaging, several third-party AI vendors and partner-developed workflow tools.

Diligence request: Review key vendor agreements, data-rights terms, SLAs, exit plans and validation workflow ownership.

Chapter 01

01Financial Information

Public sources confirm that Radiology Partners is an active private company and that a major 2024 recap occurred, but audited financial performance, full valuation support, debt detail and cap-table economics remain non-public.

EC-001 EC-002 EC-003 EC-004 EC-031 EC-032 EC-038

I.A Annual and quarterly financial information for the past three years

not publicly verifiable confidence: medium

Detailed three-year financial statements are not public, but the 2024 recap and later S&P-linked reporting provide partial evidence on liquidity and leverage stress.

EC-002 EC-004 EC-038

Evidence gaps

No audited income statements, balance sheets, cash flows, backlog schedule or AR aging were public.

Hidden risks

A recap can temporarily mask weak cash conversion if customer concentration, payer pressure or integration costs remain high.

Follow-up questions

Provide three years of audited financials, monthly management accounts and AR aging by major practice entity.

Public financial signals and missing operating metrics
metric	public signal	verification status	diligence request
Revenue / ARR / gross margin / EBITDA	Not disclosed in reviewed public sources.	not_publicly_verifiable	Provide three years of audited statements and monthly KPI bridge.
Liquidity after 2024 recap	Company said it would retain more than $500M of cash and liquidity.	verified	Reconcile reported liquidity to unrestricted cash, revolver availability and covenant definitions.
Debt-service / cash-flow stress	Independent coverage quoting S&P said higher cash interest could hinder cash flow and default risk could surface by 2027.	verified	Model debt-service coverage, practice-level cash conversion and downside cases.
Backlog / AR aging / budget-to-actuals	No public disclosure located.	not_publicly_verifiable	Request AR aging, site onboarding backlog and budget-versus-actual package.

This table is intentionally gap-heavy because RP is private and operating metrics remain non-public.

I.B Financial Projections

partially verified confidence: medium

Public financing and valuation anchors exist, but forward projections, downside cases and the valuation bridge are not public.

EC-001 EC-002 EC-003

Evidence gaps

No board plan, scenario model, capex schedule or valuation memo was public.

Hidden risks

If pricing power, site profitability or reimbursement assumptions weaken, private valuation support could unravel quickly.

Follow-up questions

Provide the current operating plan, base/bear scenarios and valuation support from the 2024 financing.

Public valuation and financing anchors chart Bar chart showing the public valuation anchor alongside the 2024 equity raise and undisclosed earlier round pricing.

I.C Capital Structure

partially verified confidence: medium

Public ownership clues indicate a physician-led, sponsor-backed structure, but current shareholdings, preferences, options and debt rights are not public.

EC-001 EC-031 EC-032

Evidence gaps

No fully diluted cap table, option pool, debt schedule or off-balance-sheet liability summary was public.

Hidden risks

Complex state-specific affiliated-practice structures can create hidden change-of-control and compliance constraints.

Follow-up questions

Provide cap table, legal-entity map, debt instruments and all potentially dilutive securities.

Capital structure and ownership snapshot
stakeholder	public position	public evidence	diligence caveat
Physicians / affiliated practice owners	Company describes itself as physician-led and physician-owned; snippet-level sources cite roughly one-third ownership pre-2024 recap.	2024 financing release and secondary snippet coverage both emphasize physician ownership.	Need current fully diluted ownership by physician entity and state-specific practice vehicles.
NEA	Long-time investor; portfolio page still lists RP as private.	NEA page shows Private status and first investment in 2012.	Current stake, board rights and preferences are not public.
Whistler Capital / Future Fund / other financial sponsors	Secondary snippet coverage indicates meaningful positions alongside physicians and NEA.	Public snippet-level ownership references cite Whistler Capital and the Future Fund among large holders.	Ownership percentages may be stale and are not cap-table proof.
Radiology Partners, Inc. versus local practice subsidiaries	Public MSO-style disclaimer says the parent is not licensed to practice medicine while local practices provide care.	Home and careers pages distinguish patient-care entities from the parent company.	Need full legal-entity map and every practice-management agreement.

Treat all public ownership percentages as provisional until reconciled to a signed cap table.

I.D Other financial information

partially verified confidence: medium

The public financing history is clearer than revenue recognition, taxes or operating-accounting detail; the 2024 recap remains the dominant public financial datapoint.

EC-002 EC-004

Evidence gaps

No public tax summary, revenue-recognition memo or debt/equity instrument register was located.

Hidden risks

Tax positions, state practice-entity cash movement and payer-arbitration receivable timing are all potential hidden issues.

Follow-up questions

Provide financing history by round, debt schedules, tax positions and accounting-policy summary.

Public funding and refinancing history
date	event	amount or term	public evidence	diligence readout
2012	NEA first investment / private-company anchor	investment amount not public on reviewed page	NEA portfolio page lists Company Status as Private and First Invested as 2012.	Supports long-running private ownership, not current cap-table economics.
2024-01-19	Refinancing and equity plan announced	new equity expected concurrently with refinancing	RP announced steps to advance its mission and said it expected to raise new equity with the refinancing transactions.	Shows recap was planned and likely motivated by capital-structure needs.
2024-02-22	Growth equity and debt refinancing closed	~$720M equity; maturities 2028-2030; >$500M liquidity	Company said it raised approximately $720M, reduced debt and extended maturities while retaining more than $500M of cash/liquidity.	Positive liquidity event, but not proof that leverage is sustainable.
2025-06-24	S&P stress commentary becomes public	default-risk commentary by 2027	Radiology Business reported S&P expected cash interest to hinder cash flow and saw loan-default risk by 2027.	Public recap story remains overshadowed by stressed-credit indicators.

Public financing history is partial and should be reconciled to signed debt and equity documents.

Funding and recap timeline Public financing and stressed-credit milestones from 2012 through 2025.

Chapter 02

02Products

Public materials support a layered offering that combines enterprise radiology services, practice infrastructure and newer AI/workflow software products, but pricing and unit economics remain private.

EC-005 EC-006 EC-007 EC-008 EC-009 EC-034

II.A Description of each product

partially verified confidence: high

Radiology Partners publicly presents a broad bundle spanning hospital services, practice support, AI deployment and emerging software platforms like RPX AI and MosaicOS.

EC-005 EC-006 EC-007 EC-008 EC-009 EC-034

Evidence gaps

No public pricing, module-level revenue, cost structure or market-share disclosures were located.

Hidden risks

A broad service-plus-software message can hide implementation drag, cannibalization or weak standalone software economics.

Follow-up questions

Provide SKU matrix, implementation playbooks, pricing, gross margins and product adoption by module.

Product and service matrix
product or service	audience	public features	verification note
Hospital and health-system service platform	Hospitals, clinics, imaging centers and referring physicians	24/7 support, subspecialty coverage, AI/ML tools, national IT infrastructure, 99.5% client-retention claim.	Enterprise posture is public; contract economics and retention methodology are not.
Practice-partner platform	Local radiology practices	IT/data, recruiting, payor contracting, billing/finance and legal/compliance support.	Publicly supports MSO-style platform breadth, but not margin split or fee structure.
Clinical AI deployment suite	RP-affiliated radiologists and practices	AI across >20M exams with partners including Aidoc, Rad AI, Subtle AI, iCAD, Qure.ai and proprietary recoMD.	Adoption and quality claims are largely company asserted.
RPX AI / AWS HealthImaging platform	Hospitals and health systems on AWS	AI orchestration and integration platform using AWS HealthImaging.	Commercial model and external adoption outside RP network are not public.
MosaicOS / Mosaic Reporting	Radiologists and affiliated practices; potentially broader enterprise imaging buyers	Cloud-native, AI-native reporting with real-time AI assistance and findings extraction.	Launch and product posture are public; software revenue contribution is not.

Feature breadth is public; attach rates, implementation effort and economics remain diligence items.

Pricing and commercial-disclosure gaps
offer	public pricing status	public signal	diligence readout
Hospital / health-system service contracts	No public rate card located	Marketing page highlights retention, support and AI/ML rather than fees.	Need contract samples, discounting and reimbursement exposure.
Practice-partner platform / MSO services	No public fee schedule located	Page lists functions such as payor contracting and billing/finance without pricing.	Need management-fee model, profit split and local-practice economics.
RPX AI	No public software pricing located	Product announced as available to hospitals and health systems on AWS.	Need software pricing, implementation cost and third-party revenue mix.
Mosaic Reporting / MosaicOS	No public pricing or packaging located	Launch announcement focuses on AI-native workflow features and installed base.	Need SKU structure, deployment cost and attach rate across existing clients.

Public pricing opacity is expected for enterprise healthcare services but still impairs competitive benchmarking.

Public service and AI architecture map High-level view of RP’s publicly visible services, users and software layers.

Chapter 03

03Customer Information

Radiology Partners has substantial public scale and partnership signals, but customer concentration, supplier spend and relationship economics are largely private; Trinity and Envision events show both growth and churn dynamics.

EC-008 EC-010 EC-011 EC-012 EC-013 EC-014 EC-015 EC-016 EC-035

III.A Top customers by application

partially verified confidence: medium

Public sources show a large facility footprint and some affiliate evidence, but not a top-15 customer list or customer ranking by application.

EC-008 EC-013 EC-014 EC-015

Evidence gaps

No top-customer list, application-level purchase history or site-level revenue file was public.

Hidden risks

One or two large health-system or payer relationships could drive outsized economics without being visible publicly.

Follow-up questions

Provide top customers by revenue and application for the last two fiscal years plus current YTD.

Public customers, affiliates and site-scale signals
customer or signal	application or scope	public evidence	verification note
Facility footprint claim	National radiology, technology and AI solutions	Mosaic launch page says RP serves more than 3,400 hospitals and other healthcare facilities.	Scale claim does not reveal revenue concentration or active versus historical sites.
2023 client-site claim	Network scale for RPX AI launch	AWS-related launch cited more than 3,300 client sites and 3,600 radiologists.	Useful for trend line but still company sourced.
Jefferson Radiology affiliate	Integrated regional affiliate across seven hospital groups	Jefferson Radiology says it is a proud affiliate of Radiology Partners with partnerships across seven hospital groups.	Third-party corroboration of affiliation; contract economics not public.
Envision transition sites	Service continuity across transitioned customer base	RP said it was preserving trusted relationships across approximately 95 client sites.	Transition volume is public, but long-term retention is not.
Trinity Health Mid-Atlantic loss	Relationship severance / exclusivity reversal	Public reporting said the prior relationship with Rad Partners ended and Trinity announced a new exclusive group.	Important churn signal but not enough to extrapolate overall churn rate.

Top-15 customer ranking and customer-level revenue remain private.

III.B Strategic relationships

partially verified confidence: medium

AWS, IKS, RADPAIR, Stanford and transition-related relationships are all public, but economics and dependency terms are not.

EC-008 EC-010 EC-011 EC-012 EC-015

Evidence gaps

No public revenue contribution, sourced pipeline, exclusivity terms or termination rights were located for these partnerships.

Hidden risks

Partnership headlines can obscure weak economics, fragile exclusivity or unbalanced IP ownership.

Follow-up questions

Provide all material partner agreements, revenue contribution by partner and a dependency heatmap.

Strategic relationships and partnerships
partner	relationship	public evidence	gap or risk
AWS	Infrastructure and imaging-data platform partner for RPX AI	RP said RPX AI uses AWS HealthImaging and is available to hospitals and health systems on AWS.	Need economics, exclusivity, cloud-spend concentration and data-portability terms.
IKS Health	GenAI-enabled workflow and care-enablement partnership	IKS described use of its Gen AI-powered Care Enablement Platform for RP workflows.	Need implementation scope, commercial terms and sourced revenue contribution.
RADPAIR	Co-development of advanced AI-driven reporting tools	RADPAIR announced a strategic partnership and co-development agenda.	Need IP ownership, roadmap control and product commercialization split.
Stanford Radiology AIDE Lab	AI safety collaboration	RP announced a strategic partnership to advance AI safety in radiology.	Need study design, validation rights and publication/IP terms.
Envision transition clients	Transition-driven site acquisition / continuity support	RP said it would support continuity across approximately 95 client sites while onboarding up to 400 radiologists.	Integration and service-quality risk can be high during large transitions.

Partnership announcements do not disclose revenue share, exclusivity, indemnities or termination rights.

III.C Revenue by customer

not publicly verifiable confidence: medium

Public sources provide facility counts and some affiliated-site clues, but not revenue by customer or identification of any customer exceeding 5% of revenue.

EC-035

Evidence gaps

No revenue-by-customer schedule, top-account concentrations or net-revenue-retention data were public.

Hidden risks

A highly concentrated contract base can create financing and operational fragility even when total site counts look large.

Follow-up questions

Provide revenue by customer and payer, with any account at or above 5% of revenue clearly flagged.

Public customer-disclosure anchors versus missing concentration data Bar chart comparing public scale disclosures to the absence of customer-level revenue concentration.

III.D Significant relationships severed within the last two years

partially verified confidence: high

The Trinity Health Mid-Atlantic relationship change in 2024 is a concrete public example of a significant relationship ending or being restructured.

EC-016

Evidence gaps

No public log of all severed relationships or root-cause analysis was located.

Hidden risks

A visible churn event can signal service, governance or local-control concerns that do not show up in aggregate retention claims.

Follow-up questions

Provide all customer, partner and supplier terminations in the last two years and the associated root causes.

III.E Top suppliers

partially verified confidence: medium

Public sources reveal important technology suppliers and dependencies, but not top-supplier spend or concentration by vendor.

EC-007 EC-008 EC-009 EC-024

Evidence gaps

No public supplier spend, SLAs, uptime commitments or termination penalties were located.

Hidden risks

Vendor concentration can hide under a seemingly diverse tool stack if one cloud or data platform is indispensable.

Follow-up questions

Provide top-supplier schedules, cloud-spend summary and key vendor contracts.

Supplier, cloud and AI dependency clues
supplier or dependency	role	public evidence	concentration risk
AWS HealthImaging	Core cloud imaging infrastructure for RPX AI	RPX AI announcement explicitly references AWS HealthImaging and AWS availability.	Potential infrastructure and data-portability concentration; spend not public.
Aidoc / Rad AI / Subtle AI / iCAD / Qure.ai	Named third-party clinical AI tools within RP deployment stack	RP AI deployment release names these tools as part of broad AI deployment.	Multiple vendors can reduce single-vendor risk but increase integration, validation and contract complexity.
Cognita Imaging / Mosaic foundation models	Underlying models for Mosaic Reporting	Mosaic launch references foundation models developed by Cognita Imaging.	Need data-rights, model-governance and vendor-dependency review.
Google Analytics	Web analytics on public digital properties	Privacy policy says RP uses Google Analytics.	Low operational risk but relevant to privacy/cookie compliance.

Supplier spend, uptime SLAs and termination rights remain private.

Chapter 04

04Competition

The public competitive picture suggests RP sits among national outsourced-radiology and teleradiology platforms, differentiating on breadth, local-practice integration and AI tooling more than on transparent pricing.

EC-016 EC-017 EC-018 EC-034

IV.A Competitive landscape by market segment

partially verified confidence: medium

Public competition evidence suggests RP competes with national teleradiology and outsourced imaging-service groups, with differentiation centered on breadth, local integration and AI enablement.

EC-016 EC-017 EC-018 EC-034

Evidence gaps

No public win/loss records, pricing comparisons or buyer reference interviews were available.

Hidden risks

Healthcare buyers may benchmark RP against lower-cost remote-read vendors even if RP sees itself as a broader platform.

Follow-up questions

Provide win/loss data, pricing benchmarks and top buyer objections against named competitors.

Competitor comparison matrix
competitor	segment	public signal	product overlap	diligence note
Radiology Partners	National radiology practice / platform	RP publicly markets hospital and practice platform plus AI/software layers.	Reference company.	Need to determine how much value comes from services versus software layers.
vRad	National teleradiology	Appears in public top-teleradiology snippet alongside RP.	24/7 remote radiology coverage and enterprise-volume service overlap.	Compare subspecialty quality, pricing and AI adoption in buyer interviews.
ONRAD	Teleradiology provider	Appears in public top-teleradiology snippet alongside RP.	Remote-read service overlap; probably less practice-platform breadth.	Assess if ONRAD competes more on speed/price than on integrated platform depth.
StatRad	Teleradiology provider	Appears in public top-teleradiology snippet alongside RP.	Remote emergency and after-hours reading overlap.	Review whether RP wins on breadth and local integration or loses on flexibility/price.
Large outsourced / outpatient imaging groups	Regional or national imaging-services platforms	Trinity press release criticized outsourcing to large-scale radiology corporations.	Hospital-system outsourcing and practice affiliation overlap.	Customer pushback can be aimed at the category, not just at RP specifically.

Competition evidence is adequate for a public-screen matrix but not for detailed win/loss analysis.

Basis-of-competition scoring
axis	rp public position	likely competitor pressure	evidence
Scale and site coverage	High; public claims of 3,300+ sites / 3,400+ facilities.	National teleradiology and platform rivals can also compete on scale.	Company and partner scale claims plus public competitor-set snippet.
Local practice integration	High; practice page emphasizes local autonomy plus national services.	Independent groups and some regional imaging platforms may compete on local control.	Practice-partner page and Trinity backlash example.
AI/workflow enablement	High; clinical AI stack, RPX AI and Mosaic platform are all public.	Specialized workflow vendors and teleradiology firms may narrow the gap over time.	AI deployment, AWS and Mosaic announcements.
Pricing transparency	Low transparency; no public rate cards found in sampled pages.	Opaque enterprise pricing likely common, but it limits external benchmarking.	Sampled public pages describe offerings without prices.

This table is an analyst synthesis and should be validated with buyer references and win/loss records.

Competitive positioning market map Analyst positioning of RP against publicly surfaced teleradiology and imaging-service competitors.

Chapter 05

05Marketing, Sales, and Distribution

RP’s public GTM is multi-sided and recruiting-intensive, aimed at hospitals, practices and clinicians, but productivity, budget and pipeline metrics remain private.

EC-005 EC-006 EC-008 EC-012 EC-019 EC-020 EC-021 EC-036

V.A Strategy and implementation

partially verified confidence: high

Public messaging is highly segmented by audience and leans on service quality, AI enablement, local autonomy and national scale.

EC-005 EC-006 EC-019

Evidence gaps

No public distribution economics, international detail or campaign ROI data were located.

Hidden risks

A broad message can conceal divergent economics across hospital, practice and recruiting channels.

Follow-up questions

Provide channel revenue mix, sourced pipeline by motion and any regional expansion plan.

Distribution channels and GTM motions
channel or motion	public evidence	region or scope	gap
Direct enterprise selling to hospitals and health systems	Dedicated partner page with retention, coverage, AI/ML and IT claims.	United States / enterprise buyers	No public pricing, sales-cycle or conversion metrics.
Practice affiliation / MSO-style expansion	Practice page markets contracting, billing, legal/compliance and recruiting support.	Radiology practices across the U.S.	Need economics of management agreements and local autonomy retention.
Transition-driven growth / integration	Envision transition release references approximately 95 client sites and up to 400 radiologists onboarding.	Large transition / consolidation events	Need post-transition retention, implementation cost and service quality outcomes.
Clinician recruiting as capacity channel	Join page, radiologist careers and open-job snippets highlight active recruiting and remote work.	National clinician and support hiring	Need fill rates, compensation cost and productivity assumptions.

Public GTM evidence is directional; pipeline and productivity data remain private.

V.B Major Customers

partially verified confidence: medium

Public major-customer evidence is limited to affiliate and site-count signals; the Trinity break shows why deeper major-account diligence is necessary.

EC-014 EC-015 EC-016 EC-035

Evidence gaps

No public trend data on major-customer growth, at-risk renewals or pipeline by named account was found.

Hidden risks

A single large-system loss can have disproportionate impact in enterprise radiology services.

Follow-up questions

Provide top-customer health scores, renewal pipeline and any major-account save plan.

V.C Principal avenues for generating new business

partially verified confidence: medium

Public evidence suggests new business is generated through direct enterprise sales, practice affiliation, partner channels, transition events and clinician recruiting.

EC-015 EC-019 EC-020

Evidence gaps

No public sourced-pipeline, conversion or new-logo breakdown by growth avenue was located.

Hidden risks

Transition-led growth can raise integration and service-quality risk if recruiting lags onboarding commitments.

Follow-up questions

Provide sourced-pipeline by channel, new-logo mix and integration success metrics for transition-led growth.

Public marketing and pipeline signals
signal	date or context	public evidence	diligence readout
Segmented website messaging	Current home and partner pages	Public web presence is tailored to hospitals, practices, radiologists and support teammates.	Supports a multi-sided GTM motion rather than a single product funnel.
RSNA / AWS event marketing	2023 AWS HealthImaging launch	RP promoted demos at RSNA 2023 and participation at AWS re:Invent alongside the RPX AI launch.	Conference-led enterprise marketing appears important for productized offerings.
RADPAIR joint conference presence	2024 strategic partnership	RADPAIR release referenced RSNA booth activity around the partnership.	Partner channels may support lead generation and category signaling.
Employer-brand marketing	Current careers footprint	Great Place to Work messaging, remote-role promotion and partnership incentives are public.	Recruiting appears to be a major go-to-market support function for capacity creation.

Public signals indicate activity but not lead quality, conversion or CAC.

Public GTM and distribution scale anchors Bar chart showing the main public counts that illustrate RP’s route-to-market scale and capacity.

V.D Sales force productivity model

not publicly verifiable confidence: medium

Public recruiting pages and job activity show capacity-building effort, but quota, sales cycle and sales-comp design are not public.

EC-020 EC-021 EC-036

Evidence gaps

No public quota, attainment, sales-cycle or sales-comp disclosures were located.

Hidden risks

If recruiting is serving as a hidden substitute for weak sales efficiency or retention, the public footprint may overstate operating strength.

Follow-up questions

Provide quota model, comp plan, sales cycle and productivity dashboard.

V.E Ability to implement marketing plan with current and projected budgets

not publicly verifiable confidence: medium

There is enough public marketing and recruiting activity to show ongoing spend, but not enough to assess whether current or projected budgets can support the plan.

EC-019 EC-020 EC-036

Evidence gaps

No public marketing budget, hiring plan cost or campaign ROI data was found.

Hidden risks

If leverage pressure persists, marketing and recruiting intensity may become harder to sustain than public activity implies.

Follow-up questions

Provide current and projected GTM budgets, hiring plan and expected payback assumptions.

Chapter 06

06Research and Development

Public R&D evidence centers on clinical AI deployment, cloud orchestration, AI-safety partnerships and AI-native reporting, but development cost, validation and monetization detail are private.

EC-007 EC-008 EC-009 EC-010 EC-012 EC-022 EC-023 EC-028

VI.A Description of R&D organization

partially verified confidence: high

Public biographies and AI deployment announcements point to an R&D posture embedded in clinical operations, IT leadership and partner ecosystems.

EC-007 EC-022 EC-023

Evidence gaps

No public R&D org chart, budget, engineering headcount or model-governance committee materials were located.

Hidden risks

Operationally embedded AI can create clinical-liability exposure if model governance trails deployment scale.

Follow-up questions

Provide R&D org chart, engineering/product headcount and AI governance committee charter.

Key R&D, clinical technology and AI leadership
name	role	public relevance	source note
Denis Zerr	Chief Information and Technology Officer	Technology executive anchor for enterprise systems and platform strategy.	Leadership page biography.
Jennifer Beaumont	Senior Vice President, Clinical Technology Services	Operational bridge between healthcare IT and clinical service delivery.	Leadership page biography.
Frank Castellano, MD	Associate Chief Medical Officer, Clinical Operations	Publicly tied to implementation of clinical programs, IT and AI tools.	Leadership page biography.
Byron Christie, MD	Associate Chief Medical Officer, Clinical Operations	Publicly tied to AI/IT implementation and partner-practice operations.	Leadership page biography.
Rich Whitney	Chairman and Chief Executive Officer	Strategic leadership anchor overseeing capital allocation and platform direction.	Leadership page biography.

This is a public leadership slice, not a full R&D org chart or software-engineering roster.

R&D and AI ecosystem architecture Public view of the people, platforms and partners involved in RP’s AI and workflow roadmap.

VI.B New Product Pipeline

partially verified confidence: medium

The public pipeline includes RPX AI, Stanford AI-safety work, RADPAIR co-development and the 2026 MosaicOS/Mosaic Reporting launch, but cost and timing detail remain sparse.

EC-008 EC-009 EC-010 EC-012 EC-028

Evidence gaps

No public development cost, launch cadence, milestone burndown or portfolio-prioritization framework was found.

Hidden risks

Product launches can be strategically meaningful while still failing to add margin or withstand regulatory scrutiny.

Follow-up questions

Provide product roadmap, launch calendar, R&D budget and model validation package by major product.

Public R&D and product pipeline
project	status	expected impact	verification note
Clinical AI deployment across 20M+ exams	Publicly described as deployed in 2023	Workflow acceleration, triage and augmented reporting across existing network.	Scale and adoption remain largely company asserted.
RPX AI / AWS HealthImaging	Launched publicly in 2023	Cloud-based orchestration layer and possible software revenue path.	External adoption and pricing not public.
Stanford AIDE Lab AI safety partnership	Announced in January 2026	Safety, validation and credibility support for clinical AI deployment.	Need scope, timelines and rights allocation.
RADPAIR co-developed reporting tools	Announced in December 2024	Generative AI reporting features layered into radiology workflows.	Need IP ownership and commercialization terms.
MosaicOS / Mosaic Reporting	Commercial launch in June 2026	AI-native reporting and operating system for radiology workflows.	Need customer rollout metrics and revenue mix.

Pipeline visibility is good by private-company standards, but cost of development and milestone economics remain private.

Chapter 07

07Management and Personnel

Public leadership and hiring signals are strong enough to confirm an active operating platform, but headcount, attrition, compensation and incentive structures are not publicly transparent.

EC-020 EC-021 EC-022 EC-023 EC-037

VII.A Organization Chart

partially verified confidence: medium

A simplified public leadership map can be assembled from biographies, but a full internal organization chart is not public.

EC-022 EC-023

Evidence gaps

No official internal org chart or span-of-control detail was public.

Hidden risks

A public leadership bench can still mask thin second-line depth or concentrated decision-making.

Follow-up questions

Provide current org chart and role/accountability matrix for executive and regional leaders.

Public leadership map Simplified org chart based on public biographies rather than internal reporting documents.

VII.B Historical and projected headcount by function and location

partially verified confidence: medium

Public workforce evidence shows a large radiologist network and active recruiting, but enterprise headcount, location mix and two-year trend data are not public in a standardized form.

EC-007 EC-012 EC-015 EC-020 EC-021

Evidence gaps

No public HRIS export, geographic headcount split or annual attrition dataset was found.

Hidden risks

Rapid onboarding or heavy remote staffing can raise training, quality and retention risks if management bandwidth is thin.

Follow-up questions

Provide historical and current headcount by function and location, plus planned hiring by role.

Headcount and hiring signals
signal	date	public evidence	readout
Radiologists in network	2023-11-13	AI deployment page referenced RP’s 3,600 radiologists.	Useful baseline for network scale, but not total employee count.
Radiologists in network	2024-12-02	RADPAIR partnership referenced more than 3,900 radiologists.	Shows continued scale growth in public narrative.
Potential onboarding volume	2025-04-30	Envision transition release anticipated onboarding up to 400 radiologists.	Highlights integration and staffing complexity.
Third-party employee estimate	2026-06-17	TrueUp search snippet said 2,000 people work at Radiology Partners.	Directional only; definitions may differ from radiologist count and employee count.
Open jobs	2026-06-17	Indeed and Glassdoor snippets cited roughly 215-220 open jobs; careers pages promote remote roles.	Strong sign of active hiring, not necessarily net growth.

Public workforce signals mix radiologists, employees and job postings, so they should not be treated as one harmonized metric.

Public workforce anchors over time Bar chart showing the best public headcount-related anchors currently available.

VII.C Senior management biographies

verified confidence: high

Public biographies for the CEO and several senior leaders are available and provide meaningful background for diligence interviews.

EC-022

Evidence gaps

A comprehensive management roster, tenure list and board-governance pack were not public.

Hidden risks

Public bios say little about succession depth, internal mobility or performance under financial stress.

Follow-up questions

Provide full management roster, board composition, succession planning and tenure data.

Senior management roster
name	role	public tenure or background	source
Rich Whitney	Chairman and Chief Executive Officer	Co-founder; previously CFO of DaVita and adviser to NEA.	RP leadership page
Cameron Cleeton	Chief Development Officer	Prior DaVita international development and physician-group acquisition experience.	RP leadership page
Denis Zerr	Chief Information and Technology Officer	Prior CHI and Amgen information-technology leadership.	RP leadership page
Tim Burke	Senior Vice President and Chief Compliance Officer	Joined RP in 2019; prior DaVita compliance and PwC background.	RP leadership page
Ryan Check	Senior Vice President and Managing General Counsel, Operations	Joined RP in 2020 from RP’s vRad practice; handles operations-side legal support.	RP leadership page
Jennifer Beaumont	Senior Vice President, Clinical Technology Services	Joined RP in 2014 after serving as CIO for Radiology Imaging Consultants.	RP leadership page

Roster is limited to public biographies rather than a full management census.

VII.D Compensation arrangements

partially verified confidence: medium

Public careers materials mention partnership and performance incentives, but key employment agreements, benefit plans and compensation design are not public.

EC-020 EC-037

Evidence gaps

No public executive employment agreements, benefits schedule or compensation philosophy pack was found.

Hidden risks

Misaligned physician and management incentives can hide inside partnership rhetoric.

Follow-up questions

Provide executive employment agreements, benefits summary and performance-compensation framework.

VII.E Incentive stock plans

not publicly verifiable confidence: medium

Incentive stock or comparable equity-plan terms are not public; the clearest public clue is generic reference to partnership and performance incentives.

EC-037

Evidence gaps

No public option plan, equity plan or partnership-unit schedule was found.

Hidden risks

Equity or partnership structures can materially affect control, physician alignment and transaction proceeds.

Follow-up questions

Provide all incentive stock, option or partnership-plan documents and current dilution tables.

VII.F Significant employee relations problems, past or present

inconclusive confidence: low

No major confirmed public employee-relations controversy surfaced in this pass, but public evidence is too thin to conclude the absence of such issues.

EC-020 EC-021

Evidence gaps

No public labor-dispute register, WARN history or employee-relations log was reviewed.

Hidden risks

Private clinician dissatisfaction or local-practice conflict can remain hidden until customer service or retention deteriorates.

Follow-up questions

Provide any material employee-relations disputes, WARN notices or retention hot spots over the last two years.

VII.G Personnel Turnover

inconclusive confidence: medium

Public data on turnover is weak and mostly indirect; open-job volume and recruiting activity show motion, not actual attrition.

EC-020 EC-021 EC-037

Evidence gaps

No public two-year turnover dataset or retention-program outcome data was found.

Hidden risks

If turnover is concentrated in certain specialties or night/weekend coverage, public aggregate hiring could hide delivery strain.

Follow-up questions

Provide turnover by role, region and specialty, plus retention-program metrics for the last two years.

Turnover, retention and employee-relations signal table
area	public signal	confidence	diligence readout
Clinician attraction / retention	Radiologist careers page highlights flexible remote roles, partnership and performance incentives.	medium	Useful retention pitch, but actual turnover, fill rate and compensation cost are not public.
Open-hiring footprint	Third-party snippets show roughly 215-220 open jobs and a 2,000-employee estimate.	medium	Could reflect growth, backfill or attrition; cannot infer turnover cleanly.
Employee-relations controversy	No major confirmed public labor action surfaced in this pass; evidence remains anecdotal and incomplete.	low	Need HRIS attrition, engagement surveys, WARN history and labor/dispute log.
Compensation / incentive detail	Public materials mention partnership and performance incentives but not detailed plans.	medium	Need employment agreements, benefits summaries and any incentive or equity plan documents.

Public workforce evidence is sufficient to show activity but not enough to underwrite retention risk.

Chapter 08

08Legal and Related Matters

The clearest public legal risk is the Aetna dispute and its No Surprises Act / corporate-practice allegations, partially offset by dismissal in 2026; privacy/compliance posture is visible publicly, but regulator correspondence and contract/insurance detail are not.

EC-016 EC-024 EC-025 EC-026 EC-027 EC-028 EC-029 EC-031 EC-033

VIII.A Pending lawsuits against the Company

verified confidence: high

The Aetna lawsuit is the clearest public case against RP, and although public reporting later said it was dismissed, the allegations remain relevant to diligence.

EC-016 EC-025 EC-026

Evidence gaps

No public reserve analysis, insurance response or outside-counsel risk memo was located.

Hidden risks

Even dismissed payer litigation can foreshadow copycat disputes, reserve needs or reimbursement-process changes.

Follow-up questions

Provide pleadings, dismissal order, reserve analysis and current status of any related payer disputes.

Pending lawsuits against the company
case	court or source	filed or published	status or issue
Aetna Health Inc. v. Radiology Partners, Inc.	CourtListener docket / federal court coverage	2024-12-23	Aetna alleged fraud worth tens of millions; public reporting later said the case was dismissed in April 2026.
Aetna dispute / No Surprises Act and corporate-practice allegations	Source on Healthcare analysis	2025-02-17	Article said the suit alleged manipulation of the No Surprises Act process.
Category-level relationship backlash	Radiology Business / Trinity public statements	2024-07-08 / 2024-06-30	Not a lawsuit, but a visible sign that outsourced-radiology relationships can become politically or operationally contentious.

Only one major directly named public lawsuit was confidently surfaced in this pass; counsel should run a full entity-name docket search.

Legal and relationship timeline Timeline of the most visible public legal, compliance-adjacent and relationship events surfaced.

VIII.B Pending lawsuits initiated by Company

inconclusive confidence: low

This pass did not surface a clearly material affirmative lawsuit initiated by RP; the strongest public court activity found was defensive motion practice in the Aetna dispute.

EC-029

Evidence gaps

No comprehensive docket search across all subsidiaries and affiliates was performed.

Hidden risks

Outbound litigation at local-practice level can remain hidden if only the parent brand is searched.

Follow-up questions

Have counsel run a full docket search across all RP entities, major affiliates and key local practice names.

Lawsuits initiated by company or defensive motion activity
matter	public position	source	diligence note
Aetna response motions by RP and Mori, Bean and Brooks	Publicly described as motions to dismiss and compel arbitration; defensive rather than affirmative litigation.	RP company response page, 2025-02-26	Do not misclassify this as an RP-initiated plaintiff action.
Material affirmative lawsuits initiated by RP	No clearly material affirmative suit was surfaced in this public pass.	Public-web quick pass	Need full local-practice and subsidiary docket search to confirm.

This table is intentionally cautious because quick public searching cannot substitute for counsel-grade docket review.

VIII.C Environmental and employee safety issues and liabilities

partially verified confidence: medium

Public materials show a privacy notice, compliance hotline, patient-safety concern channel and climate-risk report link, but no detailed environmental or safety liability record.

EC-024 EC-033

Evidence gaps

No public incident register, patient-safety log or environmental-liability summary was found.

Hidden risks

Healthcare service companies can have meaningful patient-safety or privacy incidents without broad public visibility.

Follow-up questions

Provide patient-safety event summary, privacy incident log and any environmental or safety-related liabilities.

VIII.D Material patents, copyrights, licenses, and trademarks

partially verified confidence: high

The strongest public IP evidence in this pass was a trademark footprint around MOSAIC, RECOMD and RP branding rather than a clearly surfaced patent portfolio.

EC-028

Evidence gaps

No public patent schedule, key license inventory or copyright ownership memo was located.

Hidden risks

If key AI or workflow functionality depends on licensed third-party technology, trademark ownership alone will not protect economics.

Follow-up questions

Provide patent list, key licenses, open-source policy and IP assignment confirmations.

Material IP and trademark snapshot
asset	jurisdiction or type	status	evidence
MOSAIC	U.S. trademark application / software brand	Public filing surfaced	Mark description covers AI-based software for clinical data, imaging workflows and radiology operations.
RECOMD POWERED BY RP RADIOLOGY PARTNERS	U.S. trademark branding signal	Public owner-page listing surfaced	Justia owner page lists the mark under Radiology Partners, Inc.
RP logo / Radiology Partners marks	Trademark / brand asset	Public filing mirror surfaced	USPTO.report snippet associates the mark with Radiology Partners, Inc.
Patent portfolio	Patents	Not clearly surfaced in quick public pass	Most public IP evidence located in this pass was trademark-oriented rather than patent-oriented.

Patent, license and data-rights diligence remains open despite clear trademark activity.

VIII.E Insurance coverage and material exposures

not publicly verifiable confidence: medium

Insurance coverage is not publicly disclosed, but litigation and privacy obligations show clear categories of exposure that should be insured.

EC-024 EC-025

Evidence gaps

No public policy schedules, claims history or reserve memo was located.

Hidden risks

Healthcare professional liability, cyber and billing-defense coverage can be narrow or expensive even when headline policies exist.

Follow-up questions

Provide all active insurance policies, limits, deductibles, exclusions and open claims.

VIII.F Material contracts

not publicly verifiable confidence: medium

Public partnership and structure announcements imply significant contracts exist, but the actual practice-management, payer, vendor and partnership agreements are not public.

EC-010 EC-011 EC-012 EC-031

Evidence gaps

No material contract register, sample payer agreement or practice-management contract was public.

Hidden risks

Change-of-control restrictions, non-competes, indemnities or state-law workarounds may sit inside non-public contracts.

Follow-up questions

Provide material contracts list and the top payer, practice, vendor and AI-partner agreements.

VIII.G Regulatory agency problems

inconclusive confidence: medium

Targeted public searching did not reveal a clear direct agency action naming RP, but civil litigation and the public MSO structure still justify a high-priority regulatory diligence workstream.

EC-024 EC-025 EC-027 EC-031

Evidence gaps

No regulator correspondence log, audit summary or government-inquiry register was public.

Hidden risks

An absence of public enforcement can reflect confidentiality or reporting lag rather than clean compliance.

Follow-up questions

Provide all material government and payer inquiries, audit results and outside-counsel assessments of corporate-practice and NSA compliance.

Regulatory, privacy and compliance action table
item	date or context	public evidence	diligence readout
Direct OCR/FTC/DOJ/CMS/state-AG action naming RP	Targeted search as of 2026-06-17	No clear direct agency action surfaced in targeted search-result review.	Helpful negative signal, but not proof that no regulatory matter exists.
HIPAA/privacy and breach-notice obligations	Current privacy policy and 2026 NPP	Company says PHI is governed by its NPP and that it is required by law to maintain privacy and notify in the event of a breach.	Baseline compliance posture exists; incident history and audits still needed.
Compliance hotline and privacy officer	Current company materials	Public materials list compliance@radpartners.com and a 24/7 hotline with anonymous reporting option.	Positive governance signal, but not evidence of effectiveness.
Civil allegations with regulatory flavor	2024-2026 Aetna dispute	Civil litigation alleged misuse of the No Surprises Act process and corporate-practice structures.	Even after dismissal, these allegations elevate compliance and process-review priority.

Agency-action absence is inherently less reliable than official confirmation; counsel should verify directly.

Risk heatmap Heatmap of the report’s full risk register.

Evidence

Evidence claims
ID	Claim	Status	Sources
EC-001	Radiology Partners remained an active private company as of 2026-06-17.	verified high	SRC-008 SRC-009 SRC-001
EC-002	Radiology Partners publicly disclosed a February 2024 recap with approximately $720M of new equity, reduced debt, maturities extended to 2028-2030 and more than $500M of liquidity.	verified high	SRC-006 SRC-007
EC-003	Public snippets and secondary coverage place Radiology Partners at roughly a $4B valuation after the 2024 capital raise.	partially verified medium	SRC-011 SRC-021 SRC-010
EC-004	Public S&P-linked coverage signals continuing leverage and cash-flow risk despite the 2024 recap.	verified high	SRC-030 SRC-031
EC-005	Radiology Partners publicly markets a hospital and health-system offering built around national IT infrastructure, 24/7 support, AI/ML tools and a 99.5% client retention claim.	verified high	SRC-002
EC-006	Radiology Partners publicly markets a practice-partner offering spanning IT/data, recruiting, payor contracting, billing/finance and legal/compliance functions.	verified high	SRC-003
EC-007	Radiology Partners said in 2023 that it had deployed clinical AI across more than 20 million annual exams and that more than 2,600 of its 3,600 radiologists used at least one AI tool.	partially verified medium	SRC-004
EC-008	Radiology Partners publicly launched RPX AI as an AI orchestration and integration platform built with AWS HealthImaging and described it as available to hospitals and health systems on AWS.	partially verified medium	SRC-005
EC-009	Radiology Partners publicly launched Mosaic Reporting as part of MosaicOS in June 2026 and said the AI-native system was already deployed to thousands of radiologists.	partially verified medium	SRC-035
EC-010	Radiology Partners publicly announced a strategic partnership with Stanford Radiology’s AIDE Lab to advance AI safety in radiology.	verified high	SRC-034
EC-011	IKS Health publicly announced a partnership with Radiology Partners centered on a Gen AI-powered Care Enablement Platform.	verified high	SRC-012
EC-012	RADPAIR publicly announced a strategic partnership with Radiology Partners to co-develop AI reporting tools and described RP’s network as exceeding 3,900 radiologists.	partially verified medium	SRC-013
EC-013	Radiology Partners publicly said in June 2026 that it was serving more than 3,400 hospitals and other healthcare facilities with radiology, technology and AI solutions.	partially verified medium	SRC-035
EC-014	Jefferson Radiology publicly identifies itself as a proud affiliate of Radiology Partners and says it maintains integrated and collaborative partnerships with seven hospital groups across Connecticut and Massachusetts.	verified high	SRC-014
EC-015	Radiology Partners said in April 2025 that an Envision radiology-services transition would preserve relationships across approximately 95 client sites and onboard up to 400 radiologists.	verified high	SRC-015
EC-016	A publicly reported Trinity Health Mid-Atlantic relationship tied to a former RP-affiliated group ended in 2024 and was replaced by a newly formed exclusive radiology group.	verified high	SRC-016 SRC-017
EC-017	Public search-result snippets identify a visible competitive set including ALM Teleradiology, vRad, Radiology Partners, ONRAD and StatRad for enterprise or high-volume facilities.	inconclusive medium	SRC-033
EC-018	Radiology Partners appears to compete on national service breadth, local-practice integration, AI tooling and reliability rather than transparent self-serve pricing.	partially verified medium	SRC-002 SRC-003 SRC-033
EC-019	Radiology Partners publicly segments its GTM around hospitals and health systems, radiology practices, radiologists/clinicians and support teammates.	verified high	SRC-001 SRC-002 SRC-003 SRC-019
EC-020	Radiology Partners maintains active recruiting pages that emphasize flexible remote radiology work, 24/7 technical support, paths to partnership and performance incentives.	verified high	SRC-019 SRC-020
EC-021	Third-party public snippets suggest roughly 2,000 employees and roughly 215-220 open jobs, but these numbers vary and are not company audited.	inconclusive medium	SRC-021
EC-022	Radiology Partners publicly presents a sizable healthcare leadership bench led by co-founder Rich Whitney, with named executives in technology, compliance, development and operations.	verified high	SRC-018
EC-023	Public executive biographies tie clinical operations leaders directly to implementation of clinical programs, IT and AI tools.	verified high	SRC-018
EC-024	Radiology Partners publicly discloses HIPAA-related privacy obligations, Google Analytics usage, a privacy officer contact and a compliance hotline.	verified high	SRC-022 SRC-023
EC-025	Aetna publicly sued Radiology Partners in December 2024 alleging fraud worth tens of millions of dollars and misuse of No Surprises Act and corporate-practice structures.	verified high	SRC-024 SRC-025
EC-026	A public April 2026 trade-press report said a judge dismissed the CVS-Aetna lawsuit against Radiology Partners.	verified high	SRC-026
EC-027	Targeted public searches did not surface a clear OCR, FTC, DOJ, CMS or state-AG action naming Radiology Partners itself as of 2026-06-17.	inconclusive medium	SRC-027
EC-028	The most visible public IP evidence in this pass was trademarks, including MOSAIC and RECOMD POWERED BY RP RADIOLOGY PARTNERS, rather than a clearly surfaced patent portfolio.	verified high	SRC-028 SRC-029
EC-029	The clearest public litigation activity found from Radiology Partners on the plaintiff side was defensive motion practice in the Aetna dispute, not a clearly material affirmative suit initiated by RP.	inconclusive low	SRC-032
EC-031	Radiology Partners publicly states that Radiology Partners, Inc. itself is not licensed to practice medicine and that patient care is provided by owned or managed practice subsidiaries.	verified high	SRC-001 SRC-019
EC-032	Public snippet-level ownership references describe a physician stake alongside Whistler Capital, NEA and the Future Fund, but these are not cap-table proof.	inconclusive low	SRC-036
EC-033	Radiology Partners publicly exposes a patient-safety reporting channel and links a climate-risk report, but public evidence of material environmental liabilities was not surfaced in this pass.	partially verified medium	SRC-019 SRC-037
EC-034	Sampled public RP product and partner pages did not disclose list pricing or standardized rate cards for services, RPX AI or Mosaic products.	inconclusive medium	SRC-002 SRC-003 SRC-005 SRC-035
EC-035	Public sources surfaced scale and selected affiliate or transition-site counts, but not customer-level revenue concentration or a top-15 customer schedule.	not publicly verifiable medium	SRC-013 SRC-014 SRC-015 SRC-035
EC-036	Public GTM materials and hiring pages do not disclose CAC, quota, sales-cycle, conversion or marketing-budget data.	not publicly verifiable medium	SRC-019 SRC-020 SRC-021
EC-037	Public careers materials mention partnership and performance incentives but do not disclose detailed employment agreements, benefits plans or stock/incentive-plan terms.	partially verified medium	SRC-019 SRC-020
EC-038	Reviewed public sources discussed financing, liquidity, scale and selected legal issues but did not disclose audited revenue, ARR, gross margin, backlog or AR-aging detail.	not publicly verifiable medium	SRC-006 SRC-007 SRC-010 SRC-030

Sources
ID	Publisher	Title	Accessed
SRC-001	Radiology Partners	Radiology Partners home page	2026-06-17
SRC-002	Radiology Partners	Radiology Partners hospitals and health systems partner page	2026-06-17
SRC-003	Radiology Partners	Radiology Partners radiology practices partner page	2026-06-17
SRC-004	Radiology Partners	Radiology Partners deploys clinical AI across more than 20 million annual patient exams	2026-06-17
SRC-005	Radiology Partners	Radiology Partners launches AI integration platform with AWS HealthImaging	2026-06-17
SRC-006	Radiology Partners	Radiology Partners takes steps to advance its mission of transforming radiology	2026-06-17
SRC-007	Radiology Partners	Radiology Partners closes $720 million growth equity investment and completes debt refinancing transactions	2026-06-17
SRC-008	New Enterprise Associates	NEA portfolio page for Radiology Partners	2026-06-17
SRC-009	CB Insights	CB Insights company page for Radiology Partners	2026-06-17
SRC-010	CB Insights	CB Insights financials page for Radiology Partners	2026-06-17
SRC-011	DuckDuckGo via r.jina.ai	DuckDuckGo search results for Radiology Partners valuation around $4 billion	2026-06-17
SRC-012	IKS Health	IKS Health announces partnership with Radiology Partners	2026-06-17
SRC-013	RADPAIR	RADPAIR and Radiology Partners strategic partnership press release	2026-06-17
SRC-014	Jefferson Radiology	Jefferson Radiology partnerships page	2026-06-17
SRC-015	Radiology Partners	Radiology Partners to support continuity in Envision radiology-services transition	2026-06-17
SRC-016	Radiology Business	Hospital system forms new radiology group after relationship with Rad Partners dissolves	2026-06-17
SRC-017	Trinity Health Mid-Atlantic	Trinity Health Mid-Atlantic forms exclusive partnership with newly formed radiology group	2026-06-17
SRC-018	Radiology Partners	Radiology Partners Our Team page	2026-06-17
SRC-019	Radiology Partners	Radiology Partners Join Our Team page	2026-06-17
SRC-020	Radiology Partners	Radiology Partners Radiologist Careers page	2026-06-17
SRC-021	DuckDuckGo via r.jina.ai	DuckDuckGo search results for Radiology Partners employees and jobs	2026-06-17
SRC-022	Radiology Partners Management, LLC	Radiology Partners online privacy policy	2026-06-17
SRC-023	Radiology Partners	Radiology Partners Notice of Privacy Practices 2026	2026-06-17
SRC-024	CourtListener	Aetna Health Inc. v. Radiology Partners, Inc. docket	2026-06-17
SRC-025	Source on Healthcare	Aetna suit against Radiology Partners has implications for the No Surprises Act	2026-06-17
SRC-026	Radiology Business	Judge dismisses CVS-Aetna lawsuit against Radiology Partners	2026-06-17
SRC-027	DuckDuckGo via r.jina.ai	DuckDuckGo search results for Radiology Partners and government regulators	2026-06-17
SRC-028	Justia Trademarks	Justia owner page for Radiology Partners, Inc. trademarks	2026-06-17
SRC-029	USPTO.report	USPTO.report / mark record for Radiology Partners-related MOSAIC filing	2026-06-17
SRC-030	Radiology Business	Radiology Partners constrained by high interest expenses, low cash flow generation: S&P	2026-06-17
SRC-031	Healthcare Dealflow	S&P views Radiology Partners debt refinancing maneuvers as tantamount to a default	2026-06-17
SRC-032	Radiology Partners	Radiology Partners and affiliated practice Mori, Bean and Brooks reject Aetna claims and file motions	2026-06-17
SRC-033	DuckDuckGo via r.jina.ai	DuckDuckGo search results for top teleradiology companies including Radiology Partners	2026-06-17
SRC-034	Radiology Partners	Radiology Partners and Stanford Radiology AIDE Lab launch partnership to advance AI safety in radiology	2026-06-17
SRC-035	Radiology Partners	Mosaic Clinical Technologies launches Mosaic Reporting as part of MosaicOS	2026-06-17
SRC-036	DuckDuckGo via r.jina.ai	DuckDuckGo search results for Radiology Partners ownership percentages	2026-06-17
SRC-037	Radiology Partners	Radiology Partners patient resources page	2026-06-17

Disclaimer

This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.